Esperion Therapeutics (ESPR) Competitor Comparison
We are evaluating the key criteria listed to compare Esperion Therapeutics (ESPR) against its competitors in the Biotechnology industry.
Market Capitalization
166 / 368Gross Profits
214 / 278Total Revenue
89 / 300EBITDA
256 / 337Free Cashflow
297 / 352Quick Ratio
324 / 357Earnings per Share
122 / 359Dividend yield
0 / 6Total Cash
205 / 358Performance 3 years
233 / 368Performance 5 years
307 / 368Performance 10 years
253 / 368Linearity 3 years
179 / 368Linearity 5 years
248 / 368Linearity 10 years
110 / 368Total Rank
119 / 368Dividend Rank
122 / 368Valuation Rank
142 / 368Piotroski Rank
276 / 368Muliplier Rank
56 / 368Quick Ratio - ESPR ranking 324 / 357
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.